泽璟制药-U
(688266)
| 流通市值：179.71亿 | | | 总市值：179.71亿 |
| 流通股本：2.65亿 | | | 总股本：2.65亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 384,117,191.62 | 240,696,731.58 | 108,244,408.58 | 386,438,784.02 |
| 营业收入 | 384,117,191.62 | 240,696,731.58 | 108,244,408.58 | 386,438,784.02 |
| 二、营业总成本 | 509,620,185.43 | 330,471,226.37 | 158,939,244.62 | 778,740,484.69 |
| 营业成本 | 27,024,454.43 | 17,495,980.98 | 7,149,214.53 | 29,212,095.95 |
| 税金及附加 | 867,445.09 | 563,957.23 | 235,709.79 | 1,023,163.55 |
| 销售费用 | 189,668,174.67 | 120,194,067.03 | 60,109,621.6 | 250,488,357.76 |
| 管理费用 | 41,035,357.09 | 26,420,304.17 | 14,058,987.04 | 16,560,957.75 |
| 研发费用 | 272,787,045.8 | 181,154,578.04 | 84,346,541.11 | 496,329,685.86 |
| 财务费用 | -21,762,291.65 | -15,357,661.08 | -6,960,829.45 | -14,873,776.18 |
| 其中:利息费用 | 21,794,742.26 | 15,346,029.69 | 7,012,285.59 | 22,552,728.97 |
| 其中:利息收入 | 43,673,487.35 | 30,781,852.03 | 14,516,923.48 | 39,354,994.8 |
| 加:公允价值变动收益 | 3,902,701.58 | 3,613,934.1 | 2,481,810.54 | 8,725,963.9 |
| 加:投资收益 | 2,407,009.09 | 1,561,941.83 | 505,946.82 | 5,958,525.53 |
| 信用减值损失(新) | -3,158,148.94 | -3,059,245.63 | -572,773.26 | -1,619,378.03 |
| 其他收益 | 9,803,330.56 | 8,221,905.16 | 2,655,577.65 | 81,454,190.94 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -112,548,101.52 | -79,435,959.33 | -45,624,274.29 | -297,782,398.33 |
| 加:营业外收入 | 3,681.42 | 884.96 | 442.48 | 4,955.76 |
| 减:营业外支出 | 58,304.43 | 58,301.69 | - | 1,307,069.11 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -112,602,724.53 | -79,493,376.06 | -45,623,831.81 | -299,084,511.68 |
| 减:所得税费用 | -2,956,159.52 | -1,965,711.71 | -993,045.91 | -3,949,557.69 |
| 六、净利润 | -109,646,565.01 | -77,527,664.35 | -44,630,785.9 | -295,134,953.99 |
| 持续经营净利润 | -109,646,565.01 | -77,527,664.35 | -44,630,785.9 | -295,134,953.99 |
| 归属于母公司股东的净利润 | -97,902,983.29 | -66,536,070.99 | -39,499,383.01 | -278,582,744.17 |
| 少数股东损益 | -11,743,581.72 | -10,991,593.36 | -5,131,402.89 | -16,552,209.82 |
| (一)基本每股收益 | -0.37 | -0.25 | -0.15 | -1.09 |
| (二)稀释每股收益 | -0.37 | -0.25 | -0.15 | -1.09 |
| 八、其他综合收益 | 26,035,078.95 | 338,774.7 | 104,914.23 | -2,670,887.43 |
| 归属于母公司股东的其他综合收益 | 24,168,674.87 | 284,879.39 | 79,994.91 | -3,108,162.47 |
| 九、综合收益总额 | -83,611,486.06 | -77,188,889.65 | -44,525,871.67 | -297,805,841.42 |
| 归属于母公司股东的综合收益总额 | -73,734,308.42 | -66,251,191.6 | -39,419,388.1 | -281,690,906.64 |
| 归属于少数股东的综合收益总额 | -9,877,177.64 | -10,937,698.05 | -5,106,483.57 | -16,114,934.78 |
| 公告日期 | 2024-10-26 | 2024-08-24 | 2024-04-20 | 2024-04-20 |
| 审计意见(境内) | | | | 标准无保留意见 |